Fenofibrate: Metabolic and Pleiotropic Effects
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Disturbances of lipoprotein metabolism represent one of the most important risk factors for vascular events. However, dyslipidaemic patients often have a number of additional abnormalities (such as endothelial dysfunction, hypertension, low-grade inflammation, haemostatic abnormalities and hyperuricaemia) that may accelerate the atherosclerotic process. Thus, the ideal lipid-modifying drug, along with exerting beneficial effects on lipoprotein metabolism, should also improve these coexisting disturbances. Fibric acid derivatives (fibrates) are a class of lipid-modifying drugs mainly used in patients with elevated triglyceride levels. These drugs mainly exert their actions via the activation of specific nuclear receptors called peroxisome proliferator-activated receptors alpha (PPARalpha). In this review, we summarize the current evidence suggesting that fenofibrate, one of the most widely used fibric acid derivatives, along with its well established actions on lipids also exerts several other antiatherogenic actions. Based on recently published studies, fenofibrate is a useful option for patients with primary combined dyslipidaemias or secondary dyslipidaemias, such as those associated with diabetes mellitus, metabolic syndrome or HIV infection. Additionally, in cases of refractory dyslipidaemia, the combination of fenofibrate with statins is a therapeutic option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“PPAR modulate the expression of genes involved in lipid metabolism through PPAR response elements [75-77].”
BackgroundSattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 2×
“Apo AV is a recently discovered lipoprotein that influences plasma triglyceride levels [83].”
BackgroundGuerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Chinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.20.2411 · Cited by 428
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410 · cited 2×
“The fenofibrate-induced increased lipoprotein catabolism may also be related to a PPARmediated lower hepatic Apo CIII synthesis [82].”
Background
Cited by
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
Self-citationFilippatos, T. D., Liberopoulos, E. N., Kostapanos, M., Gazi, I. F., Papavasiliou, E. C., Kiortsis, D. N., Tselepis, A. D., & Elisaf, M. S. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00733.x · Cited by 51
Self-citationEffect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C
Ncube, V., Starkey, B., & Wang, T. (2012) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2012.011163 · Cited by 21
Metadata
- Authors
- Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S., Mikhailidis, D., & Elisaf, M.
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 87-98
- ISSN
- 1570-1611 (ISSN-L)
- OpenAlex
- W2130254337
- Cited by
- 74
- References
- 16
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate: Metabolic and Pleiotropic Effects. https://app.cochat.ai/papers/10.2174/1570161052773942
- The paper
- Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S., Mikhailidis, D., & Elisaf, M. (2005). Fenofibrate: Metabolic and Pleiotropic Effects. Current Vascular Pharmacology. https://doi.org/10.2174/1570161052773942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.